Navigation Links
VIVUS to Present at Three Upcoming Investor Conferences in March
Date:2/25/2011

MOUNTAIN VIEW, Calif., Feb. 25, 2011 /PRNewswire/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that Timothy Morris, chief financial officer, will present an overview of the company at three investment conferences during the month of March.  The conference presentation schedule is as follows:Citi's 2011 Global Health Care ConferenceMarch 1, 2011 at 4:00 p.m. ETHilton New York Hotel, New York, NYCowen and Company 31st Annual Health Care ConferenceMarch 8, 2011 at 8:45 a.m. ETThe Boston Marriott Copley Place, Boston, MAROTH Capital Partners 23rd Annual OC Growth Stock ConferenceMarch 15, 2011 at 11:30 a.m. PTRitz-Carlton, Laguna Niguel, CAA live audio webcast and 30-day archive of the presentations will be available at http://ir.vivus.com.

About VIVUS VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead product in clinical development, QNEXA®, has completed phase 3 clinical trials for the treatment of obesity and is currently being considered for approval by US and EU regulators. QNEXA® is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit www.vivus.com.

CONTACT:VIVUS, Inc.Investor Relations:The Trout GroupTimothy E. MorrisBrian KorbChief Financial Officerbkorb@troutgroup.com650-934-5200646-378-2923
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. VIVUS Provides Regulatory Update on QNEXA NDA
2. VIVUS to Present at the 2011 JP Morgan Healthcare Conference
3. VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA®
4. VIVUS to Present at Two Upcoming Investor Conferences
5. VIVUS Reports Third Quarter and First Nine Months 2010 Financial Results
6. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
7. VIVUS Announces Sale of MUSE Assets to Meda
8. VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity
9. VIVUS to Host Conference Call and Webcast Discussion of Avanafil Phase 3 Results
10. VIVUS to Present at Lazard Capital Markets Healthcare Conference
11. VIVUS Announces Promotion of Peter Tam to President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... 16, 2017 Quest Diagnostics (NYSE: ... services, today announced that it has been named one ... Fortune. The annual survey designated Quest ... "Health Care: Pharmacy and Other Services" industry to attain ... company to attain the designation. This is the second ...
(Date:2/16/2017)... The global preparative and process chromatography market ... from USD 5.49 billion in 2016, at a CAGR ... type, the preparative and process chromatography market is segmented ... process chromatography segment is expected to account for the ... Growth in this segment can primarily be attributed to ...
(Date:2/16/2017)... Conn. , Feb. 16, 2017 The Lockwood ... the 2017 Best Place to Work in Connecticut ... This is the third year in a row that Lockwood ... this year to earn the number-two spot in 2017. The ... maintaining workplace excellence. The winners were determined through a survey ...
Breaking Medicine Technology:
(Date:2/17/2017)... , ... February 17, 2017 , ... ... that allow for the electronic prescribing of controlled and non-controlled substances plus the ... percent of pharmacies in the United States now accept electronic prescriptions, according to ...
(Date:2/17/2017)... ... February 17, 2017 , ... Empowering each person's mental ... for each and every seminar, session and class she offers. At the ... tools which help energize creativity, focus mental functions, enhance athletic focus and skill ...
(Date:2/17/2017)... ... February 17, 2017 , ... Access today ... Exhibition in Orlando, Fla., February 19-23. Visitors to the company’s booth (#1778) will ... used electronic patient signatures solution in healthcare . , Since it first ...
(Date:2/17/2017)... Miami, F.L. (PRWEB) , ... February 17, 2017 ... ... geared to clinical operations executives and focusing on all facets of clinical trial ... portfolio management , patient engagement, and more. In addition, attendees stopping by ...
(Date:2/17/2017)... ... ... Like most hospitals across the nation, Onslow Memorial Hospital is looking for ... Reduction Program (HRRP), the return of a patient to the hospital within 30 days ... many providers are struggling to leverage limited resources and technology, Onslow Memorial Hospital has ...
Breaking Medicine News(10 mins):